Vontobel Holding Ltd. Has $1.36 Million Stock Position in Humana Inc. (NYSE:HUM)

Vontobel Holding Ltd. lifted its holdings in shares of Humana Inc. (NYSE:HUM) by 36.5% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 5,365 shares of the insurance provider’s stock after purchasing an additional 1,434 shares during the quarter. Vontobel Holding Ltd.’s holdings in Humana were worth $1,361,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in the business. AMF Tjanstepension AB boosted its position in Humana by 166.8% in the third quarter. AMF Tjanstepension AB now owns 40,051 shares of the insurance provider’s stock valued at $12,686,000 after buying an additional 25,041 shares in the last quarter. Bleakley Financial Group LLC increased its stake in Humana by 14.8% in the third quarter. Bleakley Financial Group LLC now owns 1,841 shares of the insurance provider’s stock valued at $583,000 after purchasing an additional 237 shares in the last quarter. Stratos Wealth Advisors LLC increased its stake in Humana by 125.3% in the third quarter. Stratos Wealth Advisors LLC now owns 1,302 shares of the insurance provider’s stock valued at $412,000 after purchasing an additional 724 shares in the last quarter. Raymond James & Associates increased its position in shares of Humana by 3.5% during the third quarter. Raymond James & Associates now owns 99,530 shares of the insurance provider’s stock worth $31,525,000 after acquiring an additional 3,341 shares in the last quarter. Finally, OLD National Bancorp IN boosted its holdings in Humana by 1.8% during the third quarter. OLD National Bancorp IN now owns 2,613 shares of the insurance provider’s stock worth $828,000 after purchasing an additional 45 shares during the last quarter. 92.38% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, insider Timothy S. Huval sold 3,703 shares of the company’s stock in a transaction dated Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total transaction of $948,930.78. Following the transaction, the insider now owns 8,181 shares in the company, valued at $2,096,463.06. This represents a 31.16 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 0.32% of the stock is currently owned by corporate insiders.

Humana Trading Up 0.3 %

HUM stock opened at $253.61 on Tuesday. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.67. Humana Inc. has a twelve month low of $213.31 and a twelve month high of $406.46. The stock has a market capitalization of $30.54 billion, a price-to-earnings ratio of 22.46, a price-to-earnings-growth ratio of 2.11 and a beta of 0.56. The firm’s fifty day simple moving average is $271.27 and its two-hundred day simple moving average is $292.96.

Humana (NYSE:HUM) last issued its earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.26) by $0.10. Humana had a net margin of 1.18% and a return on equity of 13.20%. As a group, analysts anticipate that Humana Inc. will post 16.11 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on HUM shares. Royal Bank of Canada reiterated an “outperform” rating and issued a $283.00 target price on shares of Humana in a research note on Wednesday, February 12th. TD Cowen upped their price objective on shares of Humana from $261.00 to $268.00 and gave the company a “hold” rating in a research note on Monday, November 4th. Cantor Fitzgerald reissued a “neutral” rating and set a $290.00 price target on shares of Humana in a research report on Wednesday, February 12th. Morgan Stanley dropped their target price on shares of Humana from $301.00 to $285.00 and set an “equal weight” rating for the company in a research report on Wednesday, February 12th. Finally, Piper Sandler raised their price objective on shares of Humana from $270.00 to $288.00 and gave the company a “neutral” rating in a research note on Wednesday, January 15th. Nineteen equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat, Humana currently has a consensus rating of “Hold” and an average target price of $293.05.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.